Cell aggregation increases drug resistance of acute myeloid leukemia cells

被引:0
|
作者
Fadeev R.S. [1 ]
Solovieva M.E. [1 ]
Slyadovskiy D.A. [3 ]
Zakharov S.G. [4 ]
Fadeeva I.S. [1 ,2 ]
Senotov A.S. [5 ]
Dolgikh N.V. [1 ,2 ]
Golenkov A.K. [4 ]
Akatov V.S. [1 ,2 ]
机构
[1] Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow oblast
[2] Pushchino State Natural Science Institute, Pushchino, Moscow oblast
[3] Nizhni Novgorod Lobachevsky National Research University, Nizhni Novgorod
[4] Vladimirsky Moscow Regional Research Clinical Institute (MONIKI), Moscow
[5] Saratov Medical Center of the FMBA of Russia, Balakovo, Saratov oblast
基金
俄罗斯基础研究基金会;
关键词
acute myeloid leukemia; drug resistance; intercellular adhesion; multicellular aggregates;
D O I
10.1134/S1990747815020063
中图分类号
学科分类号
摘要
One of the major causes of low efficiency of the therapy for acute myeloid leukemia is drug resistance of leukemic cells. Microenvironment plays a key role in formation of the phenotype of leukemic cell drug resistance. Investigation of the mechanisms of microenvironment-mediated drug resistance is important to identify novel pharmacological targets for the acute myeloid leukemia therapy. We studied the role of cell aggregation in the drug resistance of leukemic cells. We showed the increased resistance of acute myeloid leukemia cells THP-1 to bortezomib, doxorubicin and fludarabine in multicellular aggregates. In the multicellular aggregates of THP-1 with the higher drug resistance, cell proliferation activity did not change, while the intracellular level of anti-apoptotic protein Bcl-2 increased. Inhibition of the aggregation of THP-1 cells prevented drug resistance. This work demonstrates the involvement of cell aggregation in the formation of drug resistance phenotype in leukemic cells. © 2015, Pleiades Publishing, Ltd.
引用
收藏
页码:135 / 143
页数:8
相关论文
共 50 条
  • [1] Cell Aggregation Increases Drug Resistance of Acute Myeloid Leukemia Cells
    Fadeev, R. S.
    Solovieva, M. E.
    Slyadovskiy, D. A.
    Zakharov, S. G.
    Fadeeva, I. S.
    Senotov, A. S.
    Dolgikh, N. V.
    Golenkov, A. K.
    Akatov, V. S.
    BIOLOGICHESKIE MEMBRANY, 2015, 32 (02): : 125 - 134
  • [2] Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells
    Niu, Jialan
    Peng, Danyue
    Liu, Lingbo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Drug resistance in childhood acute myeloid leukemia
    Styczynski, J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2007, 8 (02) : 59 - 75
  • [4] Bone marrow immune cells and drug resistance in acute myeloid leukemia
    Zhang, Miao
    Yang, You
    Liu, Jing
    Guo, Ling
    Guo, Qulian
    Liu, Wenjun
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2025, 250
  • [5] Assessment of drug resistance in acute myeloid leukemia
    Funato, T
    Harigae, H
    Abe, S
    Sasaki, T
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (05) : 705 - 713
  • [6] Mechanisms of drug resistance in acute myeloid leukemia
    Zhang, Jing
    Gu, Yan
    Chen, Baoan
    ONCOTARGETS AND THERAPY, 2019, 12 : 1937 - 1945
  • [7] Mechanisms of Drug Resistance in Acute Myeloid Leukemia
    N. M. Bobrova
    T. V. Romanovskaya
    Biology Bulletin Reviews, 2021, 11 (Suppl 1) : 32 - 46
  • [8] A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
    Bolandi, Seyed Mohammadreza
    Pakjoo, Mahdi
    Beigi, Peyman
    Kiani, Mohammad
    Allahgholipour, Ali
    Goudarzi, Negar
    Khorashad, Jamshid S.
    Eiring, Anna M.
    CELLS, 2021, 10 (11)
  • [9] The comprehensive evaluation on four indices of drug resistance in acute myeloid leukemia
    Chen Yan
    He Mingsheng
    Xiang Zhifu
    Wu Yudan
    Yue Beibei
    Yu Dongjiao
    Li Huiyu
    Current Medical Science, 1999, 19 (3) : 194 - 197
  • [10] Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
    Sorf, Ales
    Sucha, Simona
    Morell, Anselm
    Novotna, Eva
    Staud, Frantisek
    Zavrelova, Alzbeta
    Visek, Benjamin
    Wsol, Vladimir
    Ceckova, Martina
    CANCERS, 2020, 12 (06) : 1 - 15